Epiomic Epidemiology Series: Age-Related Macular Degeneration Forecast in 7 Major Markets 2016-2026

March 2016 | 40 pages | ID: ECFB3C21C11EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Essential Thrombocythemia (ET) in 9 Major Markets

Essential Thrombocythemia (ET) or Primary Thrombocythemia, is a rare, chronic myeloproliferative disorder that involves the over production of blood platelets by the bone marrow. ET is characterized by a persisting elevated platelet count >450,000/µL, with megakaryocytic hyperplasia, and patients will likely also suffer from splenomegaly and thrombotic or hemorrhagic episodes or both.

This report provides the current prevalent population for ET across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ET have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for ET include:

• Secondary myelofibrosis
• Acute myeloid leukaemia
• Anaemia
• Splenomegaly
• Hepatomegaly
• Incident thrombosis
• Deep vein thrombosis
• Pregnancy complications

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global ET’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ET and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ET’s prevalent population.
• Identify sub-populations within ET which require treatment.
• Gain an understanding of the specific markets that have the largest number of ET patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
  Additional data available on request
Top-Line Prevalence for Age-Related Macular Degeneration
Features of AMD Patients
  Severity and Type of AMD
  Early Type AMD
  Late Type AMD
  AMD Associated Conditions
  Exudative AMD Associated Conditions
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

AMD stages
Prevalence of AMD, total (000s)
Prevalence of AMD, males (000s)
Prevalence of AMD, females (000s)
Severity of AMD in patients, total (000s)
Early AMD by diameter (µm) of drusen present, total (000s)
Late AMD patients by type, total (000s)
Pigmentation abnormality in Early AMD patients, total (000s)
Type of CNV in Exudative AMD patients, total (000s)
Classic CNV location in Exudative AMD patients, total (000s)
Occult CNV location in Exudative AMD patients, total (000s)
Pattern of increased FAF at junctional zone in GA AMD patients, total (000s)
Prevalence of diabetes in AMD, total (000s)
Prevalence of hypertension in AMD, total (000s)
Prevalence of retinal detachment in Exudative AMD patients, total (000s)
Prevalence of subretinal haemorrhage in Exudative AMD patients, total (000s)
Prevalence of subretinal scarring in Exudative AMD patients, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of AMD by 5-yr age cohort, males (000s)
USA Prevalence of AMD by 5-yr age cohort, females (000s)
France Prevalence of AMD by 5-yr age cohort, males (000s)
France Prevalence of AMD by 5-yr age cohort, females (000s)
Germany Prevalence of AMD by 5-yr age cohort, males (000s)
Germany Prevalence of AMD by 5-yr age cohort, females (000s)
Italy Prevalence of AMD by 5-yr age cohort, males (000s)
Italy Prevalence of AMD by 5-yr age cohort, females (000s)
Spain Prevalence of AMD by 5-yr age cohort, males (000s)
Spain Prevalence of AMD by 5-yr age cohort, females (000s)
United Kingdom Prevalence of AMD by 5-yr age cohort, males (000s)
United Kingdom Prevalence of AMD by 5-yr age cohort, females (000s)
Japan Prevalence of AMD by 5-yr age cohort, males (000s)
Japan Prevalence of AMD by 5-yr age cohort, females (000s)